Logo
x

Search

Subscribe Now

discontinue

Merck KGaA and GSK Discontinue P-II INTR@PID BTC 055 Study of Bintrafusp Alfa as 1L Treatment of Biliary Tract Cancer

Merck KGaA and GSK Discontinue P-II INTR@PID BTC 055 Study of Bintrafusp Alfa as 1L Treatment of Biliary Tract Cancer

  • August 24, 2021
Galapagos and Gilead Discontinue the P-III Trials of Ziritaxestat (GLPG1690) for Idiopathic Pulmonary Fibrosis

Galapagos and Gilead Discontinue the P-III Trials of Ziritaxestat (GLPG1690) for Idiopathic Pulmonary Fibrosis

  • February 11, 2021
Santhera Halts P-III SIDEROS Study Evaluating Puldysa in Patients with DMD

Santhera Halts P-III SIDEROS Study Evaluating Puldysa in Patients with DMD

  • October 6, 2020
Halozyme to Discontinue its P-III HALO-301 Study of PEGPH20 for the Treatment of Metastatic Pancreatic Cancer

Halozyme to Discontinue its P-III HALO-301 Study of PEGPH20 for the Treatment of Metastatic Pancreatic Cancer

  • November 4, 2019
Arbutus to Discontinue its P-Ia/Ib Clinical Study of AB-506 to Treat Patients with Chronic Hepatitis B

Arbutus to Discontinue its P-Ia/Ib Clinical Study of AB-506 to Treat Patients with Chronic Hepatitis B

  • October 4, 2019
Acceleron to Discontinue its P-II Study of ACE-083 for Facioscapulohumeral Muscular Dystrophy

Acceleron to Discontinue its P-II Study of ACE-083 for Facioscapulohumeral Muscular Dystrophy

  • September 17, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.